36.11
Legend Biotech Corp Adr stock is traded at $36.11, with a volume of 909.07K.
It is down -4.40% in the last 24 hours and up +4.00% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$37.77
Open:
$37.83
24h Volume:
909.07K
Relative Volume:
0.63
Market Cap:
$6.62B
Revenue:
$520.18M
Net Income/Loss:
$-348.13M
P/E Ratio:
-18.81
EPS:
-1.92
Net Cash Flow:
$-176.18M
1W Performance:
-2.98%
1M Performance:
+4.00%
6M Performance:
-34.63%
1Y Performance:
-39.22%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LEGN
Legend Biotech Corp Adr
|
36.11 | 6.62B | 520.18M | -348.13M | -176.18M | -1.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-08-24 | Initiated | Redburn Atlantic | Buy |
Jun-17-24 | Initiated | Truist | Buy |
May-24-24 | Reiterated | H.C. Wainwright | Buy |
May-23-24 | Initiated | Deutsche Bank | Buy |
Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
Mar-13-24 | Initiated | Raymond James | Outperform |
Dec-19-23 | Initiated | Scotiabank | Sector Perform |
Nov-06-23 | Initiated | Goldman | Buy |
May-25-23 | Initiated | William Blair | Mkt Perform |
May-22-23 | Initiated | Daiwa Securities | Buy |
Mar-29-23 | Initiated | H.C. Wainwright | Buy |
Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
Dec-06-22 | Initiated | UBS | Buy |
Nov-02-22 | Initiated | Evercore ISI | Outperform |
Nov-01-22 | Initiated | Cowen | Outperform |
Oct-31-22 | Initiated | Guggenheim | Neutral |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Mar-15-22 | Initiated | Barclays | Overweight |
Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-21-21 | Initiated | Piper Sandler | Overweight |
May-18-21 | Initiated | BTIG Research | Buy |
Jul-01-20 | Initiated | JP Morgan | Overweight |
Jul-01-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Legend Biotech Corp ADR (LEGN) stock analysis: A comprehensive overview - US Post News
Beyond Meat Inc (BYND)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Deeper Dive: Understanding Legend Biotech Corp ADR (LEGN) Through its Various Ratios - The Dwinnex
Legend Biotech Corp ADR (LEGN) looking to reclaim success with recent performance - SETE News
CIMG Inc (IMG)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Ratio Analysis: Unpacking XPLR Infrastructure LP (XIFR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ratios in Focus: Analyzing Aurora Mobile Ltd ADR (JG)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyze Legend Biotech Corp ADR (NASDAQ: LEGN) Before Investing. - Stocks Register
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competition - Investing.com India
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Legend Biotech stock target cut to $91 by Jefferies - Investing.com South Africa
Legend Biotech keeps stock at Buy rating on strong position - Investing.com India
When will lagging health care stocks return to healthy growth? - The Globe and Mail
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential - Investing.com India
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti sales boost stock amid competition - Investing.com India
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook - Investing.com India
Overweight rating for Legend Biotech reflects confidence in long-term CARVYKTI revenue - Investing.com India
Legend Biotech stock hits 52-week low at $32.65 amid market challenges - Investing.com
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid challenges - Investing.com India
Legend Biotech stock hits 52-week low at $36.9 amid market shifts By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $36.9 amid market shifts - Investing.com
Analysts Expect ACWI To Hit $136 - Nasdaq
Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India
Earnings call: Legend Biotech sees robust growth with CARVICTI sales - Investing.com
Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register
Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register
Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Parkway Corporate Limited Announces New Securities Issuance - MSN
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):